BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The company is headquartered in Modiin, Central(Hamerkaz) and currently employs 24 full-time employees. The company went IPO on 2007-01-30. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
BLRX stock price ended at $3.16 on 木曜日, after rising 4.64%
On the latest trading day Jun 18, 2026, the stock price of BLRX rose by 4.64%, climbing from $3.02 to $3.16. Throughout the session, the stock experienced a volatility of 9.93%, with prices fluctuating between a daily low of $3.02 and a high of $3.32. Alongside this price increase, trading volume also rose by 4.9K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 7.8K shares were traded, amounting to a market value of approximately $13.7M.